SLAM
XENE icon

Swiss Life Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Swiss Life Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
5,319
+472
+10% +$26.2K ﹤0.01% 1223
2026
Q1 		$282K Buy
+4,847
New +$223K ﹤0.01% 1152

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss Life Asset Management's XENE Position: Q2 2026 in Review

Swiss Life Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 9.7% in Q2 2026, buying an estimated $26.2K and bringing the position to 5,319 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #1223.

Swiss Life Asset Management first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Swiss Life Asset Management held 5,319 shares of Xenon Pharmaceuticals worth $321K as of Q2 2026.
  • Swiss Life Asset Management bought 472 Xenon Pharmaceuticals shares in Q2 2026, an estimated $26.2K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1223 holding.
  • Swiss Life Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.